Vestis Corporation VSTS 深 沪
已收盘 08-14 16:00:00 美东时间
13.33
-0.190
-1.41%
华盛通- 最 高13.87
- 今 开13.53
- 成交量 141.31万股
- 最 低 13.21
- 昨 收 13.52
- 总市值 17.61亿
- 52周最高 16.90
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.98
- 委 比 -98.38%
- 总股本 1.32亿
- 历史最高 22.195
- 量 比 0.60
- 振 幅 4.88%
- 历史最低 3.98
- 每 手 1
- 风险率 3.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Did Vestis Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be r...
08-13 02:24
Baird Maintains Neutral on Vestis, Raises Price Target to $16
Baird analyst Andrew Wittmann maintains Vestis (NYSE:VSTS) with a Neutral and raises the price target from $15 to $16.
08-12 19:08
Vestis Q3 Adj. EPS $0.18 Beats $0.10 Estimate, Sales $661.663M Miss $668.991M Estimate
Vestis (NYSE:VSTS) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 1900 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $661.663 million which missed t...
08-11 19:02
Overbought industrials stocks to watch this Q2 earnings season
Industrials stocks are drawing investor attention as the second-quarter earnings season gathers momentum this week, with traders assessing whether recent gains have left some names vulnerable to profi...
07-22 21:52
Vestis updates interim CFO agreement amid leadership transition
Vestis Corporation ( ($VSTS) ) has issued an announcement. On June 12, 2026, Ve...
06-16 05:13
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
William Blair Upgrades Vestis to Outperform
William Blair analyst Tim Mulrooney upgrades Vestis (NYSE:VSTS) from Market Perform to Outperform.
05-14 04:46
